A detailed history of Smith Group Asset Management, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Smith Group Asset Management, LLC holds 9,150 shares of EXEL stock, worth $300,852. This represents 0.02% of its overall portfolio holdings.

Number of Shares
9,150
Holding current value
$300,852
% of portfolio
0.02%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 22, 2025

BUY
$25.39 - $36.46 $232,318 - $333,609
9,150 New
9,150 $305 Million
Q1 2024

Apr 30, 2024

BUY
$20.17 - $23.93 $194,035 - $230,206
9,620 New
9,620 $228 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.6B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Smith Group Asset Management, LLC Portfolio

Follow Smith Group Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith Group Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Smith Group Asset Management, LLC with notifications on news.